Original Article
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
N Engl J Med 1996; 334:677-681March 14, 1996
- Abstract
Background
Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use. We compared these two approaches.
Methods
Patients with acute proximal deep-vein thrombosis were randomly assigned to receive either intravenous standard heparin in the hospital (253 patients) or low-molecular-weight heparin (1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily) administered primarily at home (247 patients). The study design allowed outpatients taking low-molecular-weight heparin to go home immediately and hospitalized patients taking low-molecular-weight heparin to be discharged early. All the patients received warfarin starting on the second day.
Results
Thirteen of the 247 patients receiving low-molecular-weight heparin (5.3 percent) had recurrent thromboembolism, as compared with 17 of the 253 patients receiving standard heparin (6.7 percent; P = 0.57; absolute difference, 1.4 percentage points; 95 percent confidence interval, -3.0 to 5.7). Five patients receiving low-molecular-weight heparin had major bleeding, as compared with three patients receiving standard heparin. After randomization, the patients who received low-molecular-weight heparin spent a mean of 1.1 days in the hospital, as compared with 6.5 days for the standard-heparin group; 120 patients in the low-molecular-weight–heparin group did not need to be hospitalized at all.
Conclusions
Low-molecular-weight heparin can be used safely and effectively to treat patients with proximal deep-vein thrombosis at home.
Media in This Article
Table 1
Base-Line Characteristics of the Study Patients.Table 2
Recurrences of Thromboembolism during the Study.Article Activity
- Article
Patients with acute proximal deep-vein thrombosis are usually treated initially in the hospital with standard (unfractionated) heparin, administered by continuous intravenous infusion for five to seven days.1 The anticoagulant response to this treatment varies markedly among patients, and therefore the dosage must be monitored by measuring the activated partial-thromboplastin time closely.1,2
Low-molecular-weight heparins, which are prepared by the depolymerization of standard heparin, have proved to be safe and effective in preventing thromboembolism in patients at high risk3 and to be at least as safe and effective as standard heparin for the treatment of acute proximal deep-vein thrombosis.4-6 In these trials, standard heparin was administered by continuous intravenous infusion, and the dosage was adjusted to keep the activated partial-thromboplastin time within a prescribed range. In contrast, the low-molecular-weight heparins were administered by subcutaneous injection in doses adjusted for the patient's weight, without laboratory monitoring. This more convenient method of administering the treatment is possible because low-molecular-weight heparins have a more predictable anticoagulant response than standard heparin, a longer plasma half-life, and better bioavailability when administered subcutaneously.7-9
Because of these properties, low-molecular-weight heparins have the potential advantage of allowing patients with proved deep-vein thrombosis to be treated at home rather than in the hospital. We carried out a randomized trial in patients with acute deep-vein thrombosis that compared the use of continuous intravenous standard heparin in the hospital with the administration of subcutaneous low-molecular-weight heparin primarily at home. Although we encouraged immediate home treatment in the case of outpatients randomly assigned to receive low-molecular-weight heparin, our study design also allowed these patients to be admitted to the hospital briefly and treated with low-molecular-weight heparin if their clinical condition precluded immediate treatment as outpatients but if they were considered to be good candidates for early discharge — that is, within four days. In addition, we included patients with proximal deep-vein thrombosis who had been admitted to the hospital at night or on a weekend, most of whom were initially treated with standard heparin, and patients who had been hospitalized for other reasons but in whom deep-vein thrombosis developed; in all cases, the study patients had to be suitable candidates for early discharge.
Methods
Study Patients
Consecutive patients in whom acute proximal deep-vein thrombosis (thrombosis involving the popliteal vein or a more proximal vein) had been confirmed by either venography or duplex ultrasonography were eligible for the study. Patients were excluded from the study if they had any of the following: two or more previous episodes of deep-vein thrombosis or pulmonary embolism; currently active bleeding, active peptic ulcer disease, or a familial bleeding disorder; concurrent symptomatic pulmonary embolism; treatment lasting more than 48 hours with standard heparin for the deep-vein thrombosis qualifying them for the study; an inability to be treated with low-molecular-weight heparin as an outpatient because of a coexisting condition (for example, cancer, infection, or stroke) or the likelihood of noncompliance; an inability to make follow-up visits to the clinic because of geographic inaccessibility; the presence of a known deficiency of antithrombin III, protein C, or protein S; or pregnancy.
The study protocol was reviewed and approved by the institutional review boards of the participating centers (see the Appendix). Informed consent was obtained from eligible patients before their assignment to a study treatment.
Study Design
Patients were assigned to undergo treatment with either low-molecular-weight heparin primarily at home or continuous intravenous standard heparin in the hospital through randomization over the telephone from a central site. The randomization was stratified according to center, mode of diagnosis (venography or ultrasonography), and category of patient. The first category of patients included those who presented as outpatients. The second category included patients with deep-vein thrombosis who were admitted at night or on a weekend, who for logistic reasons could not be enrolled in the study immediately and thus were first treated with standard heparin. The third category included patients who were hospitalized for other reasons, such as surgery, and in whom deep-vein thrombosis was subsequently diagnosed.
Treatment Regimens
The patients assigned to therapy with low-molecular-weight heparin received 1 mg of enoxaparin (Rhône–Poulenc Rorer, Montreal) per kilogram of body weight subcutaneously twice daily. The medication was supplied in 1-ml ampules, each containing 100 mg of enoxaparin (100 International Factor Xa Inhibitory Units per milligram). The patient (and a family member, if appropriate) was taught by the study nurse how to administer the study medication subcutaneously. The first dose was given by the patient under the supervision of the nurse. The medication was drawn up into 1-ml plastic syringes (Becton Dickinson, Rutherford, N.J.) similar to those used for insulin injections and was injected through a 28.5-gauge needle. In some instances the study nurse loaded a series of syringes with the study medication and sent the patient home with enough syringes for several days of treatment.
The patients randomly assigned to therapy with standard heparin were admitted to the hospital. They received a bolus dose of 5000 units intravenously, followed by a continuous infusion of 20,000 units of standard heparin in 500 ml of a 5 percent dextrose solution, with 32 ml administered per hour. The activated partial-thromboplastin time was measured 6 hours after heparin therapy began, and the dose rate was adjusted to maintain this variable in the targeted therapeutic range of 60 to 85 seconds with use of a previously published nomogram.10 This range was equivalent to a heparin level of 0.2 to 0.4 unit per milliliter as measured by titration against protamine. The prothrombin time and activated partial-thromboplastin time of the patients in this group were measured at least once daily.
The patients began to receive warfarin sodium on the evening of the second day of treatment with the study medication. The first dose of warfarin was usually 10 mg. Thereafter, each patient's prothrombin time was measured daily, and warfarin was prescribed to achieve an international normalized ratio of 2.0 to 3.0. In the outpatients, the prothrombin time was measured daily either at the outpatient hospital laboratory or a community laboratory or at the patient's home, by a staff member of a community laboratory. The study medication was discontinued when the targeted therapeutic range for the international normalized ratio was reached and maintained for two consecutive days. However, each patient should have been treated for at least five days with either low-molecular-weight heparin or standard heparin. The study nurse contacted each outpatient daily by telephone to ensure that there were no problems and to adjust the dose of warfarin. Inpatients were seen daily by the study nurse. All the patients were scheduled to receive warfarin for at least three months.
In the case of the patients admitted at night or on a weekend, the first dose of low-molecular-weight heparin was administered 30 to 60 minutes after the discontinuation of the heparin infusion. In this group, the period during which the patient had received standard heparin before randomization was considered part of the overall duration of heparin therapy.
Follow-up and Outcome Measures
All the patients underwent impedance plethysmography at entry into the study so that subsequent impedance plethysmograms could be compared with that obtained at base line. The patients were assessed monthly for three months after randomization. Each visit included a history taking, physical examination, and impedance plethysmography. All the patients were instructed to report to the clinic on an emergency basis if any symptoms developed that were suggestive of deep-vein thrombosis or pulmonary embolism.
The principal outcome events studied in this trial were symptomatic recurrent venous thromboembolism within 90 days after randomization and bleeding during the period of administration of study medication or within 48 hours after its discontinuation.
Patients with symptoms or signs of recurrent deep-vein thrombosis underwent objective testing by impedance plethysmography, duplex ultrasonography, venography, or a combination of these techniques.11,12 Recurrent deep-vein thrombosis was diagnosed if there was a constant defect of intraluminal filling on venography or if there was a lack of compressibility on duplex ultrasonography and this finding represented a change from the results of tests of the deep-vein thrombosis qualifying the patient for the study. If the results of both venography and duplex scanning were inconclusive, recurrent deep-vein thrombosis was diagnosed if the impedance plethysmogram changed from normal to abnormal. Patients with clinically suspected pulmonary embolism underwent ventilation–perfusion lung scanning, and pulmonary embolism was diagnosed if the scan was considered to indicate a high probability of pulmonary embolism or a pulmonary angiogram was positive in a patient whose lung scan did not indicate such a probability.13
Bleeding was defined as major if it was overt and associated with either a decrease in the hemoglobin level of at least 2.0 g per deciliter or a need for the transfusion of 2 or more units of blood, or if it was retroperitoneal or intracranial.14 Bleeding was defined as minor if it was overt but did not meet the other criteria for major bleeding.
All reported outcome events were reviewed by a central adjudication committee whose members were unaware of the treatment assignments.
Statistical Analysis
On the basis of comparisons of low-molecular-weight heparin with standard heparin as in-hospital treatment,4-6 we assumed that low-molecular-weight heparin would be better than standard heparin — that is, that there would be a 3 percent rate of recurrent venous thromboembolism during the first three months of follow-up, as compared with a 6 percent rate with standard heparin. Under this assumption, and with the recruitment of 500 patients, there was a 94 percent probability (power) of rejecting, at the 5 percent level, the hypothesis that the rate of recurrence with low-molecular-weight heparin would be 3 percent higher than that with standard heparin.
The rates of recurrent venous thromboembolism, bleeding, and death in the two treatment groups were compared by Fisher's exact test. Ninety-five percent confidence intervals were calculated by the method of Thomas and Gart.15
Results
Study Population
The recruitment of patients for the trial began in May 1992 and was completed in January 1995. During this period, we screened 2230 consecutive patients with acute proximal deep-vein thrombosis. Of these, 1491 were excluded for one or more of the following reasons: inability to receive outpatient therapy with low-molecular-weight heparin because of associated coexisting conditions (610 patients), concurrent symptomatic pulmonary embolism (229), previous treatment with standard heparin for more than 48 hours (137), geographic inaccessibility (116), two or more previous episodes of deep-vein thrombosis or pulmonary embolism (110), and other causes (289).
The remaining 739 patients were invited to participate in the trial, and 500 (68 percent) gave informed consent. Among those who did not give consent, the reasons for declining to participate were a desire to be admitted to the hospital (128 patients), a desire to receive standard heparin (43), an unwillingness to give themselves injections (38), a desire not to be admitted to the hospital (7), and other reasons (23).
Of the 500 patients who consented to participate in the study, 247 were randomly assigned to treatment with low-molecular-weight heparin and 253 were assigned to receive standard heparin. No patient was lost to follow-up. The base-line characteristics of the treatment groups were reasonably similar (Table 1Table 1
Base-Line Characteristics of the Study Patients.).Anticoagulant Therapy
The mean (±SD) duration of study treatment was 5.8±1.8 days in the low-molecular-weight–heparin group and 5.5±1.2 days in the standard-heparin group. In the low-molecular-weight–heparin group, 120 patients were not hospitalized at all, and 29 were admitted to the hospital to begin treatment with low-molecular-weight heparin. Of the remaining patients in that group, 76 were admitted to the hospital at night or on a weekend before randomization, and 22 had been hospitalized for other reasons, with deep-vein thrombosis developing during hospitalization. In the standard-heparin group, 2 patients refused admission to the hospital and received standard heparin subcutaneously at home with the dose adjusted according to the activated partial-thromboplastin time, 149 were randomly assigned to enter the hospital and receive standard heparin, 81 were admitted at night or on a weekend before randomization, and 21 were hospitalized for other reasons, with deep-vein thrombosis developing in the hospital. Among the patients who received standard heparin before randomization, this treatment lasted 22±12 hours in the low-molecular-weight–heparin group and 21±11 hours in the standard-heparin group.
When patients who had outcome events were excluded, 95 percent of patients assigned to low-molecular-weight heparin and 97 percent of those assigned to standard heparin received at least 11 weeks of oral anticoagulant therapy. The international normalized ratio was in the therapeutic range (between 2.0 and 3.0) 63 percent of the time in the low-molecular-weight–heparin group and 62 percent of the time in the standard-heparin group; it was below the range 19 and 21 percent of the time, respectively, and above the range 18 and 17 percent of the time.
Thromboembolism
During the 90 days after randomization, 13 patients assigned to receive low-molecular-weight heparin (5.3 percent) had symptomatic recurrent thromboembolism, as compared with 17 patients assigned to receive standard heparin (6.7 percent, P = 0.57) (Table 2Table 2
Recurrences of Thromboembolism during the Study.). Thus, there was an absolute difference of 1.4 percentage points in favor of low-molecular-weight heparin (95 percent confidence interval, -3.0 to 5.7). Two patients in the standard-heparin group had pulmonary embolism (on the day of randomization and day 6), and both died. In the low-molecular-weight–heparin group, 7 recurrences were observed in the first month after randomization, 4 in the second month, and 2 in the third month, as compared with 12, 5, and no recurrences in the standard-heparin group in the respective months.Complications Involving Bleeding
Major hemorrhagic complications occurred during the period of study-drug administration or the subsequent 48 hours in five patients assigned to receive low-molecular-weight heparin (2.0 percent) as compared with three patients assigned to receive standard heparin (1.2 percent, P = 0.50) (Table 3Table 3
Episodes of Major Bleeding in Eight Patients during the Study.). Two episodes of bleeding in the low-molecular-weight–heparin group were fatal; one patient had a subdural hematoma after a fall, and the other, who had associated thrombocytopenia due to chemotherapy and radiation, bled from an esophageal cancer. There were six episodes of minor bleeding in each group.Five patients assigned to receive low-molecular-weight heparin and three patients assigned to receive standard heparin had platelet counts below 100,000 per cubic millimeter during the period of study-drug administration; for one patient in each group, there was no apparent explanation for the low platelet count.
Mortality
During the 90-day study period, 11 patients receiving low-molecular-weight heparin died, as compared with 17 patients receiving standard heparin.
Hospital Stay
After randomization, the mean time spent in the hospital by the patients assigned to low-molecular-weight heparin was 1.1±2.9 days, as compared with 6.5±3.4 days by the patients assigned to standard heparin (Table 4Table 4
Mean (6SD) Hospital Stays of the Study Patients after Randomization, According to Treatment Group and Category of Patient.). Among the 247 patients assigned to low-molecular-weight heparin, 120 were never admitted to the hospital, and the remaining 127 spent an average of 2.2±3.8 days in the hospital after randomization.Discussion
Patients with proximal deep-vein thrombosis generally require hospitalization in order to receive standard heparin by continuous intravenous infusion. Our study shows that enoxaparin, a low-molecular-weight heparin, can be used safely and effectively to treat patients at home who have this condition. The rates of recurrent thromboembolism and major bleeding in both treatment groups were low and did not differ significantly between treatment groups. The 95 percent confidence interval for the absolute difference between rates of thrombosis indicated that outpatient therapy with enoxaparin was unlikely to be more than 3 percent worse than treatment with standard heparin. The results of our randomized trial are consistent with the findings of previous studies demonstrating that preparations of low-molecular-weight heparin are at least as effective and safe as standard heparin in the initial treatment of hospitalized patients with deep-vein thrombosis.4-6
In one study5 and a meta-analysis16 in which the two treatments were compared, there were statistically significant reductions in mortality in favor of low-molecular-weight heparin. In our study, there was a nonsignificant trend in favor of low-molecular-weight heparin.
Treating patients with acute proximal deep-vein thrombosis requires the use of heparin at first, combined with at least three months of warfarin therapy.17,18 In the early trials comparing standard heparin with low-molecular-weight heparin in hospitalized patients, venography was performed at entry into the study and approximately one week later.3,19,20 The primary outcome measure in these trials was a change in the size of the thrombus, a surrogate for clinically recurrent thrombosis. The primary outcome measure in the more recent larger trials in hospitalized patients was symptomatic recurrent venous thromboembolism.4,5 This measure was also used in our trial. We did not routinely screen our patients by ultrasonography or venography at specified times, and thus silent recurrences may have gone undetected.
This was not a double-blind study, but we took special care to minimize bias in the assessment of recurrent venous thrombosis and bleeding. Patients were instructed to report to the study team without waiting to make a scheduled visit if any symptoms compatible with recurrent deep-vein thrombosis or pulmonary embolism developed. All suspected recurrences were evaluated by objective tests, and all outcome events were evaluated by a committee unaware of the treatment assignments.
Of the 2230 patients with acute proximal deep-vein thrombosis whom we screened, 739 (33 percent) met the study criteria requiring eligibility for either immediate outpatient treatment or early discharge from the hospital. Given some of the reasons for exclusion (e.g., geographic inaccessibility), the actual proportion of patients to which the study findings are applicable may be somewhat higher.
Of the 247 patients randomly assigned to receive low-molecular-weight heparin, 120 were never admitted to the hospital, and the remaining 127 patients spent an average of 2.2 days in the hospital after randomization. The average hospital stay for all patients in this group was 1.1 days, as compared with 6.5 days for the patients receiving standard heparin. We included the patients who were discharged early in the study in order to extend the potential convenience and cost savings associated with out-of-hospital treatment with low-molecular-weight heparin to a broader population.
Two other randomized studies21,22 have also evaluated the home administration of low-molecular-weight heparin in the long-term treatment of patients with deep-vein thrombosis. In both studies, patients were first treated in the hospital with standard heparin, and then therapy with low-molecular-weight heparin was compared with therapy for three to six months with warfarin21 or subcutaneous standard heparin.22
Low-molecular-weight heparins share a number of properties, but they differ in profiles of the distribution of molecular weight, specific activities (measured as the ratio of factor Xa to factor IIa), rates of clearance from plasma, and recommended dosage regimens.3 It should not be assumed that all low-molecular-weight heparins have similar benefits. In conclusion, our study indicates that many patients with acute proximal deep-vein thrombosis can be treated safely and effectively at home with subcutaneous enoxaparin at doses adjusted for the patient's weight, increasing the convenience for the patient and reducing the cost to the health care system substantially.
Source Information
From McMaster University, Hamilton, Ont. (M.L., M.G., J.H., J.W., J.G., A.G.T., P.P., A.W.); Hamilton Civic Hospitals Research Centre, Hamilton, Ont. (M.L., M.G., J.H., S.H., A.W.); Ontario Cancer Treatment and Research Foundation, Hamilton Regional Cancer Centre, Hamilton, Ont. (M.L.); McGill University, Montreal (J.L.); Dalhousie University, Halifax, N.S. (D.A.); Laval University, Quebec, Que. (C.D., L.D.); the University of Western Ontario, London (M.K., M.C., W.B.); the University of Toronto, Toronto (W.G.); and the University of Montreal, Montreal (J.K., J.C.) — all in Canada.
Address reprint requests to Dr. Levine at the Hamilton Regional Cancer Centre, 699 Concession St., Hamilton, ON L8V 5C2, Canada.
Appendix
The following institutions, all in Canada, participated in this study.
Hamilton Civic Hospitals, Hamilton, Ont.; Chedoke–McMaster Hospitals, Hamilton, Ont.; St. Joseph's Hospital, Hamilton, Ont.; Sunnybrook Health Science Centre, Toronto; Victoria Hospital, London, Ont.; University Hospital, London, Ont.; St. Joseph's Hospital, London, Ont.; Montreal General Hospital, Montreal; Maisonneuve–Rosemont Hospital, Montreal; Hôtel-Dieu de Montréal, Montreal; St.-Sacrement Hospital, Quebec, Que.; Centre Hospitalier de l'Université Laval, Quebec, Que.; Victoria General Hospital, Halifax, N.S.; St. Paul's Hospital, Vancouver, B.C. (J. Ward); and Health Sciences Centre, St. John's, Newf. (C. Whitman).
- References
References
1
Hirsh J . Heparin. N Engl J Med 1991;324:1565-1574
Full Text | Web of Science | Medline2
Hirsh J ,van Aken WG ,Gallus AS ,Dollery CT ,Cade JF ,Yung WL . Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-695
Web of Science | Medline3
Hirsh J ,Levine MN . Low molecular weight heparin. Blood 1992;79:1-17
Web of Science | Medline4
Prandoni P ,Lensing AW ,Buller HR , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
CrossRef | Web of Science | Medline5
Hull RD ,Raskob GE ,Pineo GF , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982
Full Text | Web of Science | Medline6
Simonneau G ,Charbonnier B ,Decousus H , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-1546
CrossRef | Web of Science | Medline7
Boneu B ,Caranobe C ,Cadroy Y , et al. Pharmacokinetic studies of standard unfractionated heparin and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988;14:8-27
CrossRef | Web of Science8
Bara L ,Billaud E ,Gramond G ,Kher A ,Samama M . Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636
CrossRef | Web of Science | Medline9
Young E ,Prins M ,Levine MN ,Hirsh J . Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643
Web of Science | Medline10
Cruickshank MK ,Levine MN ,Hirsh J ,Roberts R ,Siguenza M . A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-337
CrossRef | Web of Science | Medline11
Hull RD ,Carter CJ ,Jay RM , et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983;67:901-906
CrossRef | Web of Science | Medline12
Lensing AWA ,Prandoni P ,Brandjes D , et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989;320:342-345
Full Text | Web of Science | Medline13
Hull RD ,Hirsh J ,Carter CJ , et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-899
Web of Science | Medline14
Levine MN ,Hirsh J ,Landefeld S ,Raskob G . Hemorrhagic complications of anticoagulant treatment. Chest 1992;102:Suppl 4:352S-363S
Web of Science | Medline15
Thomas DG ,Gart JJ . A table of exact confidence limits for differences and ratios of two proportions and their odds ratios. J Am Stat Assoc 1977;72:73-76
CrossRef | Web of Science16
Lensing AW ,Prins MH ,Davidson BL ,Hirsh J . Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-607
CrossRef | Web of Science | Medline17
Lagerstedt CI ,Olsson CG ,Fagher BO ,Oqvist BW ,Albrechtsson U . Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-518
CrossRef | Web of Science | Medline18
Brandjes DPM ,Heijboer H ,Buller HR ,de Rijk M ,Jagt H ,ten Cate JW . Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-1489
Full Text | Web of Science | Medline19
Holm HA ,Ly B ,Handeland GF , et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16:Suppl 2:30-37
Medline20
Bratt G ,Aberg W ,Johansson M ,Tornebohm E ,Granqvist S ,Lockner D . Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990;64:506-510
Web of Science | Medline21
Pini M ,Aiello S ,Manotti C , et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197
Web of Science | Medline22
Monreal M ,Lafoz E ,Olive A ,del Rio L ,Vedia C . Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11
Web of Science | Medline
- Citing Articles (311)
Citing Articles
1
Luis Jara Palomares, Candela Caballero Eraso, Teresa Elías Hernández, Marta Ferrer Galván, Sergio Márquez Peláez, Aurelio Cayuela, María José Alfaro, Emilia Barrot Cortés, Remedios Otero Candelera. (2011) Control ambulatorio de los pacientes con trombosis venosa profunda y cáncer: estudio de seguridad, costes e impacto presupuestario. Medicina Clínica
CrossRef2
Elie A Akl, Nawman Labedi, Irene Terrenato, Maddalena Barba, Francesca Sperati, Elena V Sempos, Paola Muti, Deborah Cook, Holger Schünemann, Elie A Akl. 2011. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. .
CrossRef3
Shervin Farahmand, Morteza Saeedi, Hooman Haji Seyed Javadi, Patricia Khashayar. (2011) High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis. The American Journal of Emergency Medicine 29:9, 1222-1226
CrossRef4
Drahomir Aujesky, Donald M Yealy. (2011) Outpatient treatment for pulmonary embolism – Authors' reply. The Lancet 378:9804, 1695-1696
CrossRef5
G. Meyer. (2011) À la recherche de la molécule idéale. Une brève histoire des anticoagulants. Revue des Maladies Respiratoires
CrossRef6
W. ZONDAG, I. C. M. MOS, D. CREEMERS-SCHILD, A. D. M. HOOGERBRUGGE, O. M. DEKKERS, J. DOLSMA, M. EIJSVOGEL, L. M. FABER, H. M. A. HOFSTEE, M. M. C. HOVENS, G. J. P. M. JONKERS, K. W. van KRALINGEN, M. J. H. A. KRUIP, T. VLASVELD, M. J. M. DE VREEDE, M. V. HUISMAN, . (2011) Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. Journal of Thrombosis and Haemostasis 9:8, 1500-1507
CrossRef7
Karen T Schultz, Tammy J Bungard. (2011) Dosing Options for Decreasing the Time to Achieve Therapeutic Anticoagulation When Reinitiating Warfarin: A Case Series. Pharmacotherapy 31:8, 793-805
CrossRef8
Matilde Rodríguez-Cerrillo, Ana Poza-Montoro, Eddita Fernandez-Diaz, Amaia Iñurrieta-Romero, Mayra Matesanz-David. (2011) Home treatment of patients with acute cholecystitis. European Journal of Internal Medicine
CrossRef9
Drahomir Aujesky, Pierre-Marie Roy, Franck Verschuren, Marc Righini, Joseph Osterwalder, Michael Egloff, Bertrand Renaud, Peter Verhamme, Roslyn A Stone, Catherine Legall, Olivier Sanchez, Nathan A Pugh, Alfred N'gako, Jacques Cornuz, Olivier Hugli, Hans-Jürg Beer, Arnaud Perrier, Michael J Fine, Donald M Yealy. (2011) Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. The Lancet 378:9785, 41-48
CrossRef10
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef11
Zafar Iqbal, Marc Cohen. (2011) Enoxaparin: a pharmacologic and clinical review. Expert Opinion on Pharmacotherapy 12:7, 1157-1170
CrossRef12
Elie A Akl, Srinivasa Rao Vasireddi, Sameer Gunukula, Maddalena Barba, Francesca Sperati, Irene Terrenato, Paola Muti, Holger Schünemann, Elie A Akl. 2011. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. .
CrossRef13
Jawed Fareed, Cafer Adiguzel, Indermohan Thethi. (2011) Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thrombosis Journal 9:1, 5
CrossRef14
Norikazu Yamada, Mashio Nakamura, Masaaki Ito. (2011) Current Status and Trends in the Treatment of Acute Pulmonary Thromboembolism. Circulation Journal
CrossRef15
Cher Heng Tan, Deepak Bedi, Raghunandan Vikram. (2011) Sonography of thrombosis of the deep veins of the extremities: Clinical perspectives and imaging review. Journal of Clinical Ultrasoundn/a-n/a
CrossRef16
Robert C. Pendleton, George M. Rodgers, Russell D. Hull. (2010) Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia. Clinics in Chest Medicine 31:4, 691-706
CrossRef17
Mehmet Kurtoglu, Cuneyt Koksoy, Ekim Hasan, Yigit Akcalı, Ozalp Karabay, Ugur Filizcan. (2010) Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. Journal of Vascular Surgery 52:5, 1262-1270
CrossRef18
M. J. KOVACS, J. D. HAWEL, J. F. REKMAN, A. LAZO-LANGNER. (2010) Ambulatory management of pulmonary embolism: a pragmatic evaluation. Journal of Thrombosis and Haemostasis 8:11, 2406-2411
CrossRef19
Joshua Phillips, Tafadzwa Makarawo, Asad Abedin, Adel Shafik, Jonathan Eaton, Adel Makar. (2010) EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER RADICAL PELVIC SURGERY FOR UROLOGICAL CANCERS. BJU International 106:8, 1110-1111
CrossRef20
Petra MG Erkens, Martin H Prins, Martin H Prins. 2010. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. .
CrossRef21
Donna Dizon-Townson. 2010. Thromboembolic Disease. , 283-307.
CrossRef22
M. J. KOVACS, S. R. KAHN, P. S. WELLS, D. A. ANDERSON, I. CHAGNON, G. LE GAL, S. SOLYMOSS, M. CROWTHER, A. PERRIER, T. RAMSAY, M. T. BETANCOURT, R. H. White, L. Vickars, M. A. RODGER. (2010) Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. Journal of Thrombosis and Haemostasis 8:9, 1926-1932
CrossRef23
S. Schulman. (2010) New aspects on treatment modalities for thromboembolic episodes. Journal of Internal Medicine 268:2, 109-119
CrossRef24
V. Meyer, S.W. Schneider, T. Görge. (2010) Antikoagulation in der Dermatologie. Der Hautarzt 61:8, 705-718
CrossRef25
Remedios Otero, Fernando Uresandi, David Jiménez, Miguel Ángel Cabezudo, Mikel Oribe, Dolores Nauffal, Francisco Conget, Consolación Rodríguez, Aurelio Cayuela. (2010) Home treatment in pulmonary embolism. Thrombosis Research 126:1, e1-e5
CrossRef26
Paul D. Stein, Fadi Matta. (2010) Acute Pulmonary Embolism. Current Problems in Cardiology 35:7, 314-376
CrossRef27
Saina Attaran, Pavlo Somov, Wael I. Awad. (2010) Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. European Journal of Cardio-Thoracic Surgery 37:6, 1384-1390
CrossRef28
M. J. AGTEROF, R. E. G. SCHUTGENS, R. J. SNIJDER, G. EPPING, H. G. PELTENBURG, E. F. M. POSTHUMA, J. A. HARDEMAN, R. VAN DER GRIEND, T. KOSTER, M. H. PRINS, D. H. BIESMA. (2010) Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. Journal of Thrombosis and Haemostasis 8:6, 1235-1241
CrossRef29
Rasanamar Sandhu, Chong-Xian Pan, Ted Wun, Danielle Harvey, Hong Zhou, Richard H. White, Helen K. Chew. (2010) The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. CancerNA-NA
CrossRef30
Andrew S. Neviaser, Charles Chang, Stephen Lyman, Alejandro Gonzales Della Valle, Steven B. Haas. (2010) High Incidence of Complications From Enoxaparin Treatment After Arthroplasty. Clinical Orthopaedics and Related Research® 468:1, 115-119
CrossRef31
Davide Imberti, Marcello Di Nisio, Maria Benedetta Donati, Anna Falanga, Angelo Ghirarduzzi, Daniele Guarneri, Franco Piovella, Rita Carlotta Santoro, Edoardo Baldini, Stefania Zampogna. (2009) Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research 124:5, e32-e40
CrossRef32
Frederick A. Spencer, Cathy Emery, Samuel W. Joffe, Luigi Pacifico, Darleen Lessard, George Reed, Joel M. Gore, Robert J. Goldberg. (2009) Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. Journal of Thrombosis and Thrombolysis 28:4, 401-409
CrossRef33
L.-C. Linke. (2009) Therapie der postoperativen Thrombose. Der Orthopäde 38:9, 812-817
CrossRef34
Rachel M. Holden, Catherine M. Clase. (2009) Use of Warfarin in People with Low Glomerular Filtration Rate or on Dialysis. Seminars in Dialysis 22:5, 503-511
CrossRef35
Katherine Monkman, Alejandro Lazo-Langner, Michael J. Kovacs. (2009) A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. Thrombosis Research 124:3, 275-280
CrossRef36
Remedios Otero Candelera, Teresa Elías Hernández, Demetrio González Vergara. (2009) Tratamiento domiciliario de la enfermedad tromboembólica venosa (ETV). Medicina Clínica 133:7, 272-276
CrossRef37
Michael H. Huo, James Muntz. (2009) Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: A review. Clinical Therapeutics 31:6, 1129-1141
CrossRef38
Peter Schenker, Oliver Vonend, Neslihan Ertas, Andreas Wunsch, Michael Schaeffer, Lars-Christian Rump, Richard Viebahn. (2009) Incidence of pancreas graft thrombosis using low-molecular-weight heparin. Clinical Transplantation 23:3, 407-414
CrossRef39
S.H. Kwon, J.H. Oh, T.-S. Seo, H.J. Ahn, H.C. Park. (2009) Percutaneous aspiration thrombectomy for the treatment of acute lower extremity deep vein thrombosis: is thrombolysis needed?. Clinical Radiology 64:5, 484-490
CrossRef40
Agnes Y.Y. Lee. (2009) Treatment of venous thromboembolism in cancer patients. Best Practice & Research Clinical Haematology 22:1, 93-101
CrossRef41
Sasha Shepperd, Helen Doll, Joanna Broad, John Gladman, Steve Iliffe, Peter Langhorne, Suzanne Richards, Finbarr Martin, Roger Harris, Sasha Shepperd. 2009. Hospital at home early discharge. .
CrossRef42
Avi Levin, Moshe Ben-Artzi, Pazit Beckerman, Guy Haber, David Varon, Arie Ben-Yehuda, Mordechai Muszkat. (2009) Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium. Drugs & Aging 26:1, 77-85
CrossRef43
Isaac E. Hall, Martin S. Andersen, Harlan M. Krumholz, Cary P. Gross. (2009) Predictors of Venous Thromboembolism in Patients with Advanced Common Solid Cancers. Journal of Cancer Epidemiology 2009, 1-9
CrossRef44
G.J. Merli, C. Kearon. (2008) Treating Acute Pulmonary Embolism: Outpatient or Inpatient or Somewhere in between. Thrombosis Research 123, S22-S28
CrossRef45
FADI MATTA, ABDO Y. YAEKOUB, PAUL D. STEIN. (2008) Human Immunodeficiency Virus Infection and Risk of Venous Thromboembolism. The American Journal of the Medical Sciences 336:5, 402-406
CrossRef46
Rahul P. Patel, Christian Narkowicz, Glenn A. Jacobson. (2008) In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose. Clinical Therapeutics 30:10, 1880-1885
CrossRef47
Elie A. Akl, Sandeep Rohilla, Maddalena Barba, Francesca Sperati, Irene Terrenato, Paola Muti, Fadi Bdair, Holger J. Schünemann. (2008) Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cancer 113:7, 1685-1694
CrossRef48
Genevieve Le Templier, Marc A Rodger. (2008) Heparin-induced osteoporosis and pregnancy. Current Opinion in Pulmonary Medicine 14:5, 403-407
CrossRef49
Maurizio Gallieni, Mario Cozzolino, Chiara Ronga, Diego Brancaccio. (2008) Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. Nature Clinical Practice Nephrology 4:9, 488-489
CrossRef50
David Jiménez, Roger D Yusen. (2008) Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Current Opinion in Pulmonary Medicine 14:5, 414-421
CrossRef51
A. N. Keeling, T. B. Kinney, M. J. Lee. (2008) Optional inferior vena caval filters: where are we now?. European Radiology 18:8, 1556-1568
CrossRef52
G. MERLI, C. FERRUFINO, J. LIN, M. HUSSEIN, D. BATTLEMAN. (2008) Hospital-based costs associated with venous thromboembolism treatment regimens. Journal of Thrombosis and Haemostasis 6:7, 1077-1086
CrossRef53
Douglas Wardrop, David Keeling. (2008) The story of the discovery of heparin and warfarin. British Journal of Haematology 141:6, 757-763
CrossRef54
Elie A Akl, Maddalena Barba, Sandeep Rohilla, Irene Terrenato, Francesca Sperati, Paola Muti, Holger Schünemann, Elie A Akl. 2008. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. .
CrossRef55
H. K. CHEW, A. M. DAVIES, T. WUN, D. HARVEY, H. ZHOU, R. H. WHITE. (2008) The incidence of venous thromboembolism among patients with primary lung cancer. Journal of Thrombosis and Haemostasis 6:4, 601-608
CrossRef56
R. Schobeß, A. Hauenherm, C. Kunze, U. Nowak-Göttl. (2008) Intraabdominale Thrombose im Verlauf einer Appendektomie. Monatsschrift Kinderheilkunde 156:4, 371-374
CrossRef57
Tapson, Victor F., . (2008) Acute Pulmonary Embolism. New England Journal of Medicine 358:10, 1037-1052
Full Text58
Elie A Akl, Sandeep Rohilla, Maddalena Barba, Francesca Sperati, Irene Terrenato, Paola Muti, Holger Schünemann, Elie A Akl. 2008. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. .
CrossRef59
Arina J. ten Cate-Hoek, Martin H. Prins. (2008) Low molecular weight heparins in cancer. Thrombosis Research 122:5, 584-598
CrossRef60
S. Middeldorp. (2008) Heparin: From animal organ extract to designer drug. Thrombosis Research 122:6, 753-762
CrossRef61
Margherita Sorino, Paolo Colonna, Leonardo De Luca, Scipione Carerj, Esmeralda Oliva, Salvatore M De Tommasi, Umberto Conti, Flaviano Iacopi, Carlo DʼAgostino, Nicola DʼAmato, Giacinto Pettinati, Vincenzo Montericcio, Annamaria Cualbu, Italo De Luca. (2007) Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). Journal of Cardiovascular Medicine 8:12, 1034-1042
CrossRef62
Fernando Uresandi, Remedios Otero, Aurelio Cayuela, Miguel Ángel Cabezudo, David Jiménez, Elena Laserna, Francisco Conget, Miquel Oribe, Dolores Nauffal. (2007) Escala de riesgo de eventos adversos a corto plazo en pacientes con tromboembolia pulmonar. Archivos de Bronconeumología 43:11, 617-622
CrossRef63
Jan Drappatz, David Schiff, Santosh Kesari, Andrew D. Norden, Patrick Y. Wen. (2007) Medical Management of Brain Tumor Patients. Neurologic Clinics 25:4, 1035-1071
CrossRef64
Amanda J. Ghanim, Constantine Daskalakis, David J. Eschelman, Walter K. Kraft. (2007) A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. Journal of Thrombosis and Thrombolysis 24:3, 247-254
CrossRef65
Beste Ozben, Nurdan Papila, M. Azra Tanrikulu, Fatih Bayalan, Ali Serdar Fak, Ahmet Oktay. (2007) Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer. Journal of Thrombosis and Thrombolysis 24:3, 317-321
CrossRef66
Thomas M. Hyers, Alex C. Spyropoulos, . (2007) Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. Journal of Thrombosis and Thrombolysis 24:3, 225-232
CrossRef67
Jeremy M. Jacobs, Aaron Cohen, Ora Rozengarten, Ludmila Meiller, Daniel Azoulay, Robert Hammerman-Rozenberg, Jochanan Stessman. (2007) Closure of a home hospital program: Impact on hospitalization rates. Archives of Gerontology and Geriatrics 45:2, 179-189
CrossRef68
Dean A Regier, Carlo A Marra, Larry Lynd. (2007) Economic evaluations of anticoagulants for the prophylaxis of venous thromboembolism following major trauma. Expert Review of Pharmacoeconomics & Outcomes Research 7:4, 403-413
CrossRef69
Richard Othieno, Mayada Abu Affan, Emmanuel Okpo, Richard Othieno. 2007. Home versus in-patient treatment for deep vein thrombosis. .
CrossRef70
Niels Seeholzer, Beat Th??rlimann, Dieter K??berle, Dagmar Hess, Wolfgang Korte. (2007) Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood Coagulation & Fibrinolysis 18:5, 415-423
CrossRef71
Allan Moore, Evan Lau, Clarissa Yang, Bonnie Mackool, David J. Kuter. (2007) Dalteparin-Induced Skin Necrosis in a Patient With Metastatic Lung Adenocarcinoma. American Journal of Clinical Oncology 30:3, 329-331
CrossRef72
Ali Civelek, Koray Ak, Ozlem Kurtkaya, Atike Tekeli, Selim Isbir, Erol Nargileci, Sinan Arsan, Aydin Sav. (2007) Effect of a Low Molecular Weight Heparin Molecule, Dalteparin, on Cellular Apoptosis and Inflammatory Process in an Incisional Wound-Healing Model. Surgery Today 37:5, 406-411
CrossRef73
Jacob P. Deerhake, Julie C. Merz, Jeanna V. Cooper, Kim A. Eagle, William P. Fay. (2007) The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. Journal of Thrombosis and Thrombolysis 23:2, 107-113
CrossRef74
David Jiménez Castro, Gema Díaz, David Martí, Carlos Escobar, Javier Ortega, Sergio García-Rull, Joaquin Picher, Antonio Sueiro. (2007) Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. Blood Coagulation & Fibrinolysis 18:2, 173-177
CrossRef75
Thomas C. Krivak, Kristin K. Zorn. (2007) Venous Thromboembolism in Obstetrics and Gynecology. Obstetrics & Gynecology 109:3, 761-777
CrossRef76
Sophie Leclerc-Foucras, Haleh Bagheri, Kamran Samii, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (2007) Modifications of Low-Molecular Weight Heparin Use in a French University Hospital after Implementation of New Guidelines. Drug Safety 30:5, 409-417
CrossRef77
Aslam M Khaja, James C Grotta. (2007) Established treatments for acute ischaemic stroke. The Lancet 369:9558, 319-330
CrossRef78
Russell D. Hull, Graham F. Pineo, Rollin F. Brant, Andrew F. Mah, Natasha Burke, Richard Dear, Turnly Wong, Roy Cook, Susan Solymoss, Man-Chiu Poon, Gary Raskob. (2007) Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms. The American Journal of Medicine 120:1, 72-82.e3
CrossRef79
Samuel Z. Goldhaber. 2007. Deep Vein Thrombosis and Pulmonary Embolism. , 245-256.
CrossRef80
Frederick R. Rickles, Mark Levine. 2007. Thrombosis and Cancer. , 389-403.
CrossRef81
Charles W. Francis. 2007. Antithrombotic Agents. , 447-460.
CrossRef82
Patrick Y. Wen, David Schiff, Santosh Kesari, Jan Drappatz, Debra C. Gigas, Lisa Doherty. (2006) Medical management of patients with brain tumors. Journal of Neuro-Oncology 80:3, 313-332
CrossRef83
Gilles L. Fraser, Richard R. Riker. (2006) Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients. Journal of Hospital Medicine 1:6, 380-381
CrossRef84
2006. Venous Thromboembolism. .
CrossRef85
Javier Trujillo-Santos, Salud Herrera, M. Angeles Page, M. José Soto, Antoni Raventós, Rosario Sánchez, Manuel Monreal. (2006) Predicting adverse outcome in outpatients with acute deep vein thrombosis. Findings from the RIETE Registry. Journal of Vascular Surgery 44:4, 789-793
CrossRef86
ANDREW S. BLUM. (2006) Endovascular Management of Deep Vein Thrombosis. Journal of Interventional Cardiology 19:s5, S97-S101
CrossRef87
M. Mandalà, A. Falanga, A. Piccioli, P. Prandoni, E.M. Pogliani, R. Labianca, S. Barni. (2006) Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM). Critical Reviews in Oncology/Hematology 59:3, 194-204
CrossRef88
A.D. Giannoukas, N. Labropoulos, J.A. Michaels. (2006) Compression with or without Early Ambulation in the Prevention of Post-thrombotic Syndrome: A Systematic Review. European Journal of Vascular and Endovascular Surgery 32:2, 217-221
CrossRef89
Frederick A. Spencer, Cathy Emery, Darleen Lessard, Frederick Anderson, Sri Emani, Jayashri Aragam, Richard C. Becker, Robert J. Goldberg. (2006) The Worcester Venous Thromboembolism Study: A Population-Based Study of the Clinical Epidemiology of Venous Thromboembolism. Journal of General Internal Medicine 21:7, 722-727
CrossRef90
Philippe de Moerloose, Charles Marc Samama, Serge Motte. (2006) Management of venous thromboembolism. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 53:S2, S80-S88
CrossRef91
Juan Ruiz Manzano. (2006) Tratamiento ambulatorio de la tromboembolia pulmonar. Medicina Clínica 127:1, 11-12
CrossRef92
A. C. SPYROPOULOS, A. G. G. TURPIE, A. S. DUNN, J. SPANDORFER, J. DOUKETIS, A. JACOBSON, F. J. FROST, . (2006) Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry1. Journal of Thrombosis and Haemostasis 4:6, 1246-1252
CrossRef93
Ramón Lecumberri, Jesús Feliu, Eduardo Rocha. (2006) Tromboembolia venosa en pacientes con cáncer. Medicina Clínica 127:1, 22-32
CrossRef94
K. Sideras, P. L. Schaefer, S. H. Okuno, J. A. Sloan, L. Kutteh, T. R. Fitch, S. R. Dakhil, R. Levitt, S. R. Alberts, R. F. Morton, K. M. Rowland, P. J. Novotny, C. L. Loprinzi. (2006) Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial. Mayo Clinic Proceedings 81:6, 758-767
CrossRef95
Jane Pruemer. (2006) Treatment of Cancer-Associated Thrombosis: Distinguishing Among Antithrombotic Agents. Seminars in Oncology 33, 26-39
CrossRef96
Regina S. Cunningham. (2006) The Role of Low-Molecular-Weight Heparins as Supportive Care Therapy in Cancer-Associated Thrombosis. Seminars in Oncology 33, 17-25
CrossRef97
T. Baglin, T. W. Barrowcliffe, A. Cohen, M Greaves, . (2006) Guidelines on the use and monitoring of heparin. British Journal of Haematology 133:1, 19-34
CrossRef98
M.S. Cunningham, B. White, J. O'Donnell. (2006) Prevention and Management of Venous Thromboembolism in People with Cancer: A Review of the Evidence. Clinical Oncology 18:2, 145-151
CrossRef99
Jeffrey I. Weitz. (2006) Changing Paradigms in the Management of Venous Thromboembolism. The American Heart Hospital Journal 4:2, 135-141
CrossRef100
H. Partsch. (2006) Ambulatorische Therapie der tiefen Venenthrombose und die Wertigkeit der Kompression. Gefässchirurgie 11:1, 22-27
CrossRef101
Barbara A Hutten, Martin H Prins, Martin H Prins. 2006. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. .
CrossRef102
John T. Wiernikowski, Uma H. Athale. (2006) Thromboembolic complications in children with cancer. Thrombosis Research 118:1, 137-152
CrossRef103
Antonio G??mez-Outes, Eduardo Rocha, Javier Mart??nez-Gonz??lez, Vijay V Kakkar. (2006) Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis. PharmacoEconomics 24:1, 81-92
CrossRef104
Erhard Hiller. (2006) Cancer and Thrombosis: Managing the Risks and Approaches to Thromboprophylaxis. Onkologie 29:10, 474-478
CrossRef105
Regina S. Cunningham. (2005) Therapeutic Options for the Treatment of Cancer-Associated Thrombosis. Seminars in Oncology Nursing 21:4, 21-40
CrossRef106
Theresa Wicklin Gillespie. (2005) Nursing Interventions in the Management of Patients with Cancer-Associated Thrombosis. Seminars in Oncology Nursing 21:4, 50-59
CrossRef107
, , , , , , , , , , , , , , , , . (2005) Interdisziplinäre S2-Leitlinie. Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie. Intensivmedizin und Notfallmedizin 42:7, 552-565
CrossRef108
Joseph A. Caprini, Victor F. Tapson, Thomas M. Hyers, Albert L. Waldo, Ann K. Wittkowsky, Richard Friedman, Kevin J. Colgan, Alicia C. Shillington. (2005) Treatment of venous thromboembolism: Adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. Journal of Vascular Surgery 42:4, 726-733
CrossRef109
Filippo Luca Fimognari, Lazzaro Repetto, Leo Moro, Walter Gianni, Raffaele Antonelli Incalzi. (2005) Age, cancer and the risk of venous thromboembolism. Critical Reviews in Oncology/Hematology 55:3, 207-212
CrossRef110
W. Blättler, H.E. Gerlach. (2005) Implementation of Outpatient Treatment of Deep-vein Thrombosis in Private Practices in Germany. European Journal of Vascular and Endovascular Surgery 30:3, 319-324
CrossRef111
Hugo Partsch. (2005) Ambulation and Compression After Deep Vein Thrombosis: Dispelling Myths. Seminars in Vascular Surgery 18:3, 148-152
CrossRef112
H. R. BULLER, M. SOHNE, S. MIDDELDORP. (2005) Treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis 3:8, 1554-1560
CrossRef113
Sasha Shepperd, Steve Iliffe, Sasha Shepperd. 2005. Hospital at home versus in-patient hospital care. .
CrossRef114
Adam R. Shprecher, Angela Cheng-Lai, Eileen M. Madsen, Hillel W. Cohen, Mark J. Sinnett, Serena T. Wong, Henny H. Billett. (2005) Peak Antifactor Xa Activity Produced by Dalteparin Treatment in Patients with Renal Impairment Compared with Controls. Pharmacotherapy 25:6, 817-822
CrossRef115
Beng H. Chong, Tim A. Brighton, Ross I. Baker, Peter Thurlow, Choon H. Lee, . (2005) Once-Daily Enoxaparin in The Outpatient Setting Versus Unfractionated Heparin in Hospital for the Treatment of Symptomatic Deep-Vein Thrombosis. Journal of Thrombosis and Thrombolysis 19:3, 173-181
CrossRef116
Takuji Yamagami, Takeharu Kato, Shigeharu Iida, Tatsuya Hirota, Tsunehiko Nishimura. (2005) Gunther Tulip Inferior Vena Cava Filter Placement During Treatment for Deep Venous Thrombosis of the Lower Extremity. CardioVascular and Interventional Radiology 28:4, 442-453
CrossRef117
Paul A Kyrle, Sabine Eichinger. (2005) Deep vein thrombosis. The Lancet 365:9465, 1163-1174
CrossRef118
Paolo Prandoni. (2005) Emerging strategies for treatment of venous thromboembolism. Expert Opinion on Emerging Drugs 10:1, 87-94
CrossRef119
S. Lange, G. Freitag. (2005) Special Invited Papers Section: Therapeutic Equivalence – Clinical Issues and Statistical Methodology in Noninferiority Trials. Biometrical Journal 47:1, 12-27
CrossRef120
Agnes Y. Y. Lee. (2005) Management of thrombosis in cancer: primary prevention and secondary prophylaxis. British Journal of Haematology 128:3, 291-302
CrossRef121
Daniel Most, Jeffrey Kozlow, Jennifer Heller, Michele A. Shermak. (2005) Thromboembolism in Plastic Surgery. Plastic and Reconstructive Surgery 115:2, 20e-30e
CrossRef122
E. Al-Yaseen, P. S. Wells, J. Anderson, J. Martin, M. J. Kovacs. (2005) The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. Journal of Thrombosis and Haemostasis 3:1, 100-102
CrossRef123
Sandra Lowery, Kathleen Haley, Henry I. Bussey. (2005) Oral Anticoagulation. Lippincott's Case Management 10:1, 39???50
CrossRef124
Timothy A. Morris, Alan Jacobson, James J. Marsh, James R. Lane. (2005) Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity. Thrombosis Research 115:1-2, 45-51
CrossRef125
Isabelle Gouin-Thibault, Eric Pautas, Virginie Siguret. (2005) Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose. Drug Safety 28:4, 333-349
CrossRef126
Nathan I. Shapiro, Jeffrey Spear, Susan Sheehy, Jeremy Brown, Jonathan A. Edlow. (2005) Barriers to the use of outpatient enoxaparin therapy in patients with deep venous thrombosis. The American Journal of Emergency Medicine 23:1, 30-34
CrossRef127
Carsten N. Gutt, Traian Oniu, Frédéric Wolkener, Ari Mehrabi, Shilu Mistry, Markus W. Büchler. (2005) Prophylaxis and treatment of deep vein thrombosis in general surgery. The American Journal of Surgery 189:1, 14-22
CrossRef128
Darlene J. Elias. (2004) Pulmonary Embolism in Orthopaedic Patients: Diagnosis and Treatment. Techniques in Orthopaedics 19:4, 317-326
CrossRef129
James Edwin Muntz. (2004) Treatment of Venous Thromboembolism in Orthopaedic Surgery. Techniques in Orthopaedics 19:4, 337-346
CrossRef130
Carlo J van Dongen, Angelique GM van den Belt, Martin H Prins, AWA Lensing, Martin H Prins. 2004. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. .
CrossRef131
David Bergqvist. (2004) Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. European Journal of Haematology 73:4, 227-242
CrossRef132
Edith A. Nutescu, Alex C. Spyropoulos, Kerry W. Cranmer. (2004) Oral Anticoagulation: Preparing for Change. Journal of the American Medical Directors Association 5:5, 2-10
CrossRef133
A. Gómez-Outes, R. Lecumberri, A. Lafuente-Guijosa, J. Martínez-González, P. Carrasco, E. Rocha. (2004) Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. Journal of Thrombosis and Haemostasis 2:9, 1581-1587
CrossRef134
Paul P. Dobesh, The Heparin Consensus Group. (2004) Economics of Unfractionated Heparin: Beyond Acquisition Cost. Pharmacotherapy 24:8 Part 2, 161S-164S
CrossRef135
Bates, Shannon M., Ginsberg, Jeffrey S., . (2004) Treatment of Deep-Vein Thrombosis. New England Journal of Medicine 351:3, 268-277
Full Text136
Vincent J. Willey, Michael F. Bullano, Ole Hauch, Matthew Reynolds, Gail Wygant, Lauren Hoffman, George Mayzell, Alex C. Spyropoulos. (2004) Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clinical Therapeutics 26:7, 1149-1159
CrossRef137
J. Harenberg, H. Riess, J. Brom, G. Weidinger. (2004) Treatment of patients initially for acute deep vein thrombosis with a low-molecular-weight heparin at a fixed, body weight-independent dosage. Journal of Thrombosis and Haemostasis 2:7, 1200-1202
CrossRef138
Hau C Kwaan, Meyer M Samama. (2004) Anticoagulant drugs: an update. Expert Review of Cardiovascular Therapy 2:4, 511-522
CrossRef139
R. D. Hull. (2004) Laboratory monitoring of low-molecular-weight heparin therapy. Journal of Thrombosis and Haemostasis 2:6, 1004-1005
CrossRef140
Daniel Farray, Teresa L Carman, Bernardo B Fernandez. (2004) The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases. Neurologic Clinics 22:2, 423-439
CrossRef141
Thomas Hofmann. (2004) Clinical application of enoxaparin. Expert Review of Cardiovascular Therapy 2:3, 321-337
CrossRef142
Shuwei Gao, Carmen Escalante. (2004) Venous thromboembolism and malignancy. Expert Review of Anticancer Therapy 4:2, 303-320
CrossRef143
Rachel Koreth, Craig Weinert, Daniel J. Weisdorf, Nigel S. Key. (2004) Measurement of bleeding severity: a critical review. Transfusion 44:4, 605-617
CrossRef144
D.F. O'Shaughnessy. (2004) Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. International Journal of Clinical Practice 58:3, 277-284
CrossRef145
Ajay K Kakkar. (2004) Low- and ultra-low-molecular-weight heparins. Best Practice & Research Clinical Haematology 17:1, 77-87
CrossRef146
Alexandra Ward, Denis Getsios, Judith O’Brien, J Jaime Caro. (2004) Economic assessments of low molecular weight heparin in venous thromboembolism. Expert Review of Pharmacoeconomics & Outcomes Research 4:1, 39-47
CrossRef147
Nilesh H. Patel. (2004) Limitations of Medical/Surgical Management of DVT. Journal of Vascular and Interventional Radiology 15:2, P62-P70
CrossRef148
S. R. Deitcher. (2004) Undue Extension of Hospital Stay Associated With Anticoagulation. Mayo Clinic Proceedings 79:2, 157-158
CrossRef149
A. Dunn, D. Bioh, M. Beran, M. Capasso, A. Siu. (2004) Effect of Intravenous Heparin Administration on Duration of Hospitalization. Mayo Clinic Proceedings 79:2, 159-163
CrossRef150
Edith A. Nutescu, Alex C. Spyropoulos, Kerry W. Cranmer. (2004) Oral Anticoagulation: Preparing for Change. Journal of the American Medical Directors Association 5:suppl, 2
CrossRef151
Eduardo Ramacciotti, Gilson R. Araújo, Sidnei Lastoria, Francisco H.A. Maffei, Liberato Karaoglan de Moura, Wilson Michaelis, João Luis Sandri, Flávia Dietrich-Neto. (2004) An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thrombosis Research 114:3, 149-153
CrossRef152
(2004) A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis 2:1, 47-53
CrossRef153
M. W. Rich. (2004) The Management of Venous Thromboembolic Disease in Older Adults. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:1, M34-M41
CrossRef154
Agnes YY Lee. (2003) Anti-thrombotic therapy in cancer patients. Expert Opinion on Pharmacotherapy 4:12, 2213-2220
CrossRef155
P B Lockhart, J Gibson, S H Pond, J Leitch. (2003) Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. British Dental Journal 195:9, 405-501
CrossRef156
Juan I Arcelus, Joseph A Caprini, Manuel Monreal, Carmen Suárez, José González-Fajardo. (2003) The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. Journal of Vascular Surgery 38:5, 916-922
CrossRef157
Daniel J Brotman, Scott Kaatz. (2003) Should patients on warfarin for 3 months for idiopathic proximal deep venous thrombosis receive bridging therapy precolonoscopy (with expected biopsy)?. Medical Clinics of North America 87:6, 1205-1214
CrossRef158
Schulman, Sam, Wåhlander, Karin, Lundström, Torbjörn, Clason, Solveig Billing, Eriksson, Henry, . (2003) Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran. New England Journal of Medicine 349:18, 1713-1721
Full Text159
Cheryl Nadeau, Jerry Varrone. (2003) Treat DVT with Low Molecular Weight Heparin. The Nurse Practitioner 28:10, 22-29
CrossRef160
S. Payne, K. MacKinnon, M. Keeney, B. Morrow, M. J. Kovacs. (2003) Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin. Clinical and Laboratory Haematology 25:5, 317-319
CrossRef161
M. M. W. Koopman, H. R. Buller. (2003) Short- and long-acting synthetic pentasaccharides. Journal of Internal Medicine 254:4, 335-342
CrossRef162
A Bellou, J.-D de Korwin, J Bouget, F Carpentier, V Ledoray, J Kopferschmitt, H Lambert. (2003) Place des services d’urgences dans la régulation des hospitalisations publiques. La Revue de Médecine Interne 24:9, 602-612
CrossRef163
A. Iorio, F. Guercini, M. Pini. (2003) Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis 1:9, 1906-1913
CrossRef164
Lee, Agnes Y.Y., Levine, Mark N., Baker, Ross I., Bowden, Chris, Kakkar, Ajay K., Prins, Martin, Rickles, Frederick R., Julian, Jim A., Haley, Susan, Kovacs, Michael J., Gent, Michael, . (2003) Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine 349:2, 146-153
Full Text165
M. N. Levine, A. Y. Lee, A. K. Kakkar. (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis and Haemostasis 1:7, 1456-1463
CrossRef166
Agnes Y.Y Lee. (2003) Epidemiology and management of venous thromboembolism in patients with cancer. Thrombosis Research 110:4, 167-172
CrossRef167
Mark N. Levine. (2003) Can we optimise treatment of thrombosis?. Cancer Treatment Reviews 29, 19-22
CrossRef168
U. Priglinger, G. Delle Karth, A. Geppert, C. Joukhadar, S. Graf, R. Berger, M. Hülsmann, S. Spitzauer, I. Pabinger, G. Heinz. (2003) Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?*. Critical Care Medicine 31:5, 1405-1409
CrossRef169
Michael Laposata, Stephen M. Johnson. (2003) Assessment of the stability of dalteparin sodium in prepared syringes for up to thirty days: An in vitro study. Clinical Therapeutics 25:4, 1219-1225
CrossRef170
Victor F Tapson. (2003) The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy. Clinics in Chest Medicine 24:1, 139-151
CrossRef171
Michel Boucher, Marc Rodger, Jeffrey A. Johnson, Mike Tierney. (2003) Shifting from Inpatient to Outpatient Treatment of Deep Vein Thrombosis in a Tertiary Care Center: A Cost-Minimization Analysis. Pharmacotherapy 23:3, 301-309
CrossRef172
Roger D Yusen, Brian F Gage. (2003) Outpatient treatment of acute venous thromboembolic disease. Clinics in Chest Medicine 24:1, 49-61
CrossRef173
Rodger L Bick, Sylvia Haas. (2003) Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. Hematology/Oncology Clinics of North America 17:1, 217-258
CrossRef174
Debra Hoppensteadt, Jeanine M. Walenga, Jawed Fareed, Rodger L. Bick. (2003) Heparin, low–molecular-weight heparins, and heparin pentasaccharide. Hematology/Oncology Clinics of North America 17:1, 313-341
CrossRef175
Charles P. Semba. (2003) Update on Thrombolysis for Lower-Extremity DVT. Journal of Vascular and Interventional Radiology 14:2, P291-P298
CrossRef176
Nilesh H. Patel. (2003) DVT—Incidence, Pathogenesis, Clinical Features and Current Systemic Therapy. Journal of Vascular and Interventional Radiology 14:2, P283-P291
CrossRef177
Geno J Merli. (2003) Current pharmacotherapeutic options for treating deep vein thrombosis. Expert Opinion on Pharmacotherapy 4:1, 55-65
CrossRef178
Enrico Bernardi, Paolo Prandoni. (2003) Safety of low molecular weight heparins in the treatment of venous thromboembolism. Expert Opinion on Drug Safety 2:1, 87-94
CrossRef179
H. Eriksson, K. W
hlander, D. Gustafsson, L.t Welin, L. Frison, S. Schulman, . (2003) A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 1:1, 41-47
CrossRef180
Douglas E. Sutherland, Ilene C. Weitz, Howard A. Liebman. (2003) Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatment. American Journal of Hematology 72:1, 43-52
CrossRef181
Jacqueline Saw, Dean J Kereiakes, Kenneth W Mahaffey, Robert J Applegate, Gregory A Braden, Bruce N Brent, Bruce R Brodie, James B Groce, Glenn N Levine, Fred Leya, David J Moliterno. (2003) Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thrombosis Research 112:5-6, 301-306
CrossRef182
Marc A Rodger, Christine Gagné-Rodger, Heather E Howley, Marc Carrier, Doug Coyle, Philip S Wells. (2003) The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thrombosis Research 112:1-2, 13-18
CrossRef183
Philip C Comp. (2003) Treatment and management of acute venous thromboembolic disease. Thrombosis Research 111:1-2, 3-8
CrossRef184
Maria J. Cuadrado. (2002) Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (hughes syndrome). Current Rheumatology Reports 4:5, 392-398
CrossRef185
Edelgard Lindhoff-Last, Roumen Nakov, Frank Misselwitz, Hans-Klaus Breddin, Rupert Bauersachs. (2002) Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. British Journal of Haematology 118:4, 1137-1142
CrossRef186
N. Cook, D. M. Thomas. (2002) Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism. Internal Medicine Journal 32:9-10, 437-444
CrossRef187
Hugo Partsch. (2002) Bed rest versus ambulation in the initial treatment of patients with proximal deep vein thrombosis. Current Opinion in Pulmonary Medicine 8:5, 389-393
CrossRef188
Job Harenberg. (2002) Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. Current Opinion in Pulmonary Medicine 8:5, 383-388
CrossRef189
Mark N Levine. (2002) Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treatment Reviews 28:3, 145-149
CrossRef190
Steven R. Deitcher, Teresa L. Carman. (2002) Deep venous thrombosis and pulmonary embolism. Current Treatment Options in Cardiovascular Medicine 4:3, 223-238
CrossRef191
U. Hoffmann, J. Harenberg, K. Bauer, G. Huhle, A. R. Tolle, M. Feuring, M. Christ. (2002) Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagulation & Fibrinolysis 13:4, 289-296
CrossRef192
N.L. Rymes, W. Lester, C. Connor, S. Chakrabarti, C.D. Fegan. (2002) Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clinical and Laboratory Haematology 24:3, 165-170
CrossRef193
Abu-Laban, Riyad B., Christenson, James M., Innes, Grant D., van Beek, Catherina A., Wanger, Karen P., McKnight, R. Douglas, MacPhail, Iain A., Puskaric, Joe, Sadowski, Richard P., Singer, Joel, Schechter, Martin T., Wood, Victor M., . (2002) Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity. New England Journal of Medicine 346:20, 1522-1528
Full Text194
Patrick Y. Wen, Peter W. Marks. (2002) Medical management of patients with brain tumors. Current Opinion in Oncology 14:3, 299-307
CrossRef195
Bernadette Porter. (2002) The Role of the Advanced Practice Nurse in Anticoagulation. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 13:2, 221-233
CrossRef196
Jacqueline A Mason, Alexander GG Turpie. (2002) Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opinion on Pharmacotherapy 3:5, 575-598
CrossRef197
David G. Fairchild, Joanne Hogan, Rebecca Smith, Michelle Portnow, David W. Bates. (2002) Survey of Primary Care Physicians and Home Care Clinicians. An Assessment of Communication and Collaboration. Journal of General Internal Medicine 17:4, 253-261
CrossRef198
Yoram Maaravi, Aaron Cohen, Robert Hammerman-Rozenberg, Jochanan Stessman. (2002) Home Hospitalization. Journal of the American Medical Directors Association 3:2, 114-118
CrossRef199
Walter Ageno. (2002) Treatment of venous thromboembolism. International Journal of Hematology 76:S2, 40-43
CrossRef200
Polona Peternel, Martina Terbižan, Gregor Tratar, Mojca Božič, Dunja Horvat, Barbara Salobir, Mojca Stegnar. (2002) Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin. Thrombosis Research 105:3, 241-246
CrossRef201
Hans Klaus Breddin. (2002) Reviparin sodium – a new low molecular weight heparin. Expert Opinion on Pharmacotherapy 3:2, 173-182
CrossRef202
M.M. Samama, M.H. Horellou, J. Conard, A. Achkar, I. Elalamy. (2002) Le traitement de la thrombose veineuse profonde par les héparines de bas poids moléculaire. Commentaires sur les recommandations du Consensus Nord-Américain. Annales de Cardiologie et d'Angéiologie 51:3, 172-176
CrossRef203
David Bergqvist. (2002) Enoxaparin. PharmacoEconomics 20:4, 225-243
CrossRef204
C. Schmidt. (2002) Traitement ambulatoire des thromboses veineuses profondes des membres inférieurs à la phase aiguë. Annales de Cardiologie et d'Angéiologie 51:3, 152-157
CrossRef205
Judith A. O??Brien, Jaime J. Caro. (2002) Direct Medical Cost of Managing Deep Vein Thrombosis According to the Occurrence of Complications. PharmacoEconomics 20:9, 603-615
CrossRef206
W. E. Wade, W. J. Spruill. (2001) Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data. Blood Coagulation & Fibrinolysis 12:8, 619-625
CrossRef207
P GIBSON, K ROSENEMONTELLA. (2001) Anticoagulants. Best Practice & Research Clinical Obstetrics & Gynaecology 15:6, 847-861
CrossRef208
DK Cundiff, J Manyemba, David Cundiff. 2001. Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.. .
CrossRef209
P. Rose, D. Bell, E.S. Green, A. Davenport, C. Fegan, H. Grech, D. O'Shaughnessy, J. Voke. (2001) The outcome of ambulatory DVT management using a multidisciplinary approach*. Clinical and Laboratory Haematology 23:5, 301-306
CrossRef210
Philip S. Wells. (2001) Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Current Opinion in Pulmonary Medicine 7:5, 360-364
CrossRef211
R ANDRES, A MILES. (2001) VENOUS THROMBOEMBOLISM AND PREGNANCY. Obstetrics and Gynecology Clinics of North America 28:3, 613-630
CrossRef212
Bruce Leff. (2001) Acute? Care at Home. Journal of the American Geriatrics Society 49:8, 1123-1125
CrossRef213
Jeroen Frank van der Heijden, Barbara A Hutten, Harry R Büller, Martin H Prins, Jeroen Frank van der Heijden. 2001. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. .
CrossRef214
M DESANCHO, J RAND. (2001) BLEEDING AND THROMBOTIC COMPLICATIONS IN CRITICALLY ILL PATIENTS WITH CANCER. Critical Care Clinics 17:3, 599-622
CrossRef215
Graham F. Pineo. (2001) New Developments in the Prevention and Treatment of Venous Thromboembolism. Pharmacotherapy 21:6 Part 2, 51S-55S
CrossRef216
Christopher R May. (2001) Management of venous thromboembolic disease in the lower limb. Emergency Medicine Australasia 13:2, 211-223
CrossRef217
Agnes Y.Y Lee. (2001) Treatment of Venous Thromboembolism in Cancer Patients. Thrombosis Research 102:6, V195-V208
CrossRef218
Enric Grau, Jose M. Tenias, Esperanza Real, Jose Medrano, Rosario Ferrer, Emilio Pastor, Salvador Selfa. (2001) Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. American Journal of Hematology 67:1, 10-14
CrossRef219
Leslie T. Busby, Anne Weyman, George M. Rodgers. (2001) Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. American Journal of Hematology 67:1, 54-56
CrossRef220
IG Schraibman, AA Milne, EM Royle, Ivor Gerald Schraibman. 2001. Home versus in-patient treatment for deep vein thrombosis. .
CrossRef221
Giancarlo Agnelli, Cecilia Becattini. (2001) Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. Seminars in Hematology 38, 58-66
CrossRef222
Alexander G.G Turpie. (2001) Looking forward in the treatment of deep-vein thrombosis. Seminars in Hematology 38, 49-57
CrossRef223
Breddin, Hans Klaus, Hach-Wunderle, Viola, Nakov, Roumen, Kakkar, Vijay V., . (2001) Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis. New England Journal of Medicine 344:9, 626-631
Full Text224
Nitin B. Chandramouli, George M. Rodgers. (2001) Management of Thrombosis in Women With Antiphospholipid Syndrome. Clinical Obstetrics and Gynecology 44:1, 36-47
CrossRef225
Maged A. Tanios, Amy R. Simon, Paul M. Hassoun. (2001) Management of Venous Thromboembolic Disease in the Chronically Critically Ill Patient. Clinics in Chest Medicine 22:1, 105-122
CrossRef226
Beth A. Duplaga, Christina W. Rivers, Edith Nutescu. (2001) Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations. Pharmacotherapy 21:2, 218-234
CrossRef227
Steven Bacsi, Rhonda Geoffrey, Gian Visentin, Raffaele De Palma, Richard Aster, Jack Gorski. (2001) Identification of T cells responding to a self-protein modified by an external agent. Human Immunology 62:2, 113-124
CrossRef228
Albert Wertheimer, Richard Levy, Thomas O'Connor. 2001. Too many drugs? The clinical and economic value of incremental innovations. , 77-118.
CrossRef229
C. Daniel Mullins, Simu K. Thomas, David S. Roffman. (2001) Pharmaceutical Restrictions. Disease Management and Health Outcomes 9:2, 69-74
CrossRef230
John A. Heit. (2001) Current Management of Acute Symptomatic Deep Vein Thrombosis. American Journal of Cardiovascular Drugs 1:1, 45-50
CrossRef231
Maxence Delomez, Jean-Paul Beregi, Serge Willoteaux, Jean-Jacques Bauchart, Bertrand Janne d’Othée, Philippe Asseman, Nessim Perez, Claude Théry. (2001) Mechanical thrombectomy in patients with deep venous thrombosis. Cardiovascular and Interventional Radiology 24:1, 42-48
CrossRef232
Ian D. Timms. (2001) Low-Molecular-Weight Heparins: Overview and Potential Uses in Interventional Radiology. Journal of Vascular and Interventional Radiology 12:1, P33-P39
CrossRef233
Kristine B. Gilbert, George M. Rodgers. (2000) Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital. American Journal of Hematology 65:4, 285-288
CrossRef234
M. F. Loreto, Massimo Martinis, M. P. Corsi, M. Modesti, L. Ginaldi. (2000) Coagulation and cancer: Implications for diagnosis and management. Pathology & Oncology Research 6:4, 301-312
CrossRef235
Timothy A Morris, James J Marsh, Ronald Konopka, Craig A Pedersen, Peter G Chiles. (2000) Anti-thrombotic Efficacies of Enoxaparin, Dalteparin, and Unfractionated Heparin in Venous Thrombo-embolism. Thrombosis Research 100:3, 185-194
CrossRef236
Werner Blättler, Nadja Kreis, Irene K. Blättler. (2000) Practicability and quality of outpatient management of acute deep venous thrombosis. Journal of Vascular Surgery 32:5, 855-860
CrossRef237
Hugo Partsch, Werner Blättler. (2000) Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. Journal of Vascular Surgery 32:5, 861-869
CrossRef238
Bernard Boneu. (2000) Low Molecular Weight Heparins. Thrombosis Research 100:2, 113-120
CrossRef239
Jeroen F van der Heijden, Martin H Prins, Harry R Büller. (2000) For the Initial Treatment of Venous Thromboembolism. Thrombosis Research 100:2, 121-130
CrossRef240
Oscar M Aguilar, Neal S Kleiman. (2000) Low molecular weight heparins. Expert Opinion on Pharmacotherapy 1:6, 1091-1103
CrossRef241
Rodger L. Bick. (2000) Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism. Drugs 60:3, 575-595
CrossRef242
F López-Jiménez. (2000) Update in Internal Medicine. Archives of Medical Research 31:4, 329-352
CrossRef243
Robert I Shulman. (2000) Assessment of low-molecular-weight heparin trials in cardiology. Pharmacology & Therapeutics 87:1, 1-9
CrossRef244
Karen Campbell Betten. (2000) The Use of Low Molecular Weight Heparin in the Initial Management of Patients with Deep Vein Thrombosis. Journal of the American Academy of Nurse Practitioners 12:7, 267-272
CrossRef245
Christopher J. Dunn, Blair Jarvis. (2000) Dalteparin. Drugs 60:1, 203-237
CrossRef246
G Agnelli, R Rossi, M.G Santamaria. (2000) Management of thromboembolism in the outpatient setting. Seminars in Hematology 37, 23-26
CrossRef247
P. de Moerloose, G. Reber, A. Perrier, T. Perneger, H. Bounameaux. (2000) Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. British Journal of Haematology 110:1, 125-129
CrossRef248
Spiros G Frangos, Alan H Chen, Bauer Sumpio. (2000) Vascular drugs in the new millennium11No competing interests declared.. Journal of the American College of Surgeons 191:1, 76-92
CrossRef249
Michael Martin. (2000) Treatment of deep vein thrombosis—a still unresolved problem. International Journal of Angiology 9:3, 202-204
CrossRef250
Khashayar Salartash, Michael Lepore, Mark D. Gonze, Andrea Leone-Bay, Robert Baughman, W. Charles Sternbergh, John C. Bowen, Samuel R. Money. (2000) Treatment of Experimentally Induced Caval Thrombosis With Oral Low Molecular Weight Heparin and Delivery Agent in a Porcine Model of Deep Venous Thrombosis. Annals of Surgery 231:6, 789-794
CrossRef251
BA Hutten, MH Prins, Martin Prins. 2000. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. .
CrossRef252
Laura J. Kelsey, Dennis M. Fry, Wayne E. VanderKolk. (2000) THROMBOSIS RISK IN THE TRAUMA PATIENT. Hematology/Oncology Clinics of North America 14:2, 417-430
CrossRef253
Mark A Crowther, Karen Spitzer, Jim Julian, Jeff Ginsberg, Marilyn Johnston, Roberta Crowther, Carl Laskin. (2000) Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients. Thrombosis Research 98:2, 133-138
CrossRef254
Thomas W Wakefield. (2000) Treatment options for venous thrombosis. Journal of Vascular Surgery 31:3, 613-620
CrossRef255
Clive Kearon, Linda Harrison, Mark Crowther, Jeffrey S Ginsberg. (2000) Optimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis. Thrombosis Research 97:6, 395-403
CrossRef256
Scott Farrell, Tim Hayes, Mary Shaw. (2000) A negative simpliRED D-Dimer Assay result does not exclude the diagnosis of deep vein thrombosis or pulmonary embolus in emergency department patients. Annals of Emergency Medicine 35:2, 121-125
CrossRef257
Carlos A. Estrada, Christopher J. Mansfield, Gustavo R. Heudebert. (2000) Cost-effectiveness of Low-Molecular-Weight Heparin in the Treatment of Proximal Deep Vein Thrombosis. Journal of General Internal Medicine 15:2, 108-115
CrossRef258
A THOMSON, I GREER. (2000) Non-haemorrhagic obstetric shock. Best Practice & Research Clinical Obstetrics & Gynaecology 14:1, 19-41
CrossRef259
Samuel Z. Goldhaber. (2000) Medical Management of Venous Thromboembolic Disease. Journal of Vascular and Interventional Radiology 11:2, 160-162
CrossRef260
Ian D. Timms. (2000) Low-Molecular-Weight Heparins. Journal of Vascular and Interventional Radiology 11:2, 392-396
CrossRef261
Robin M. Janke, Paul G. McGovern, Aaron R. Folsom. (2000) Mortality, hospital discharges, and case fatality for pulmonary embolism in the Twin Cities. Journal of Clinical Epidemiology 53:1, 103-109
CrossRef262
Walter Ageno. (2000) Treatment of Venous Thromboembolism. Thrombosis Research 97:1, V63-V72
CrossRef263
Peter J. Zed. (2000) Low molecular weight heparins and coronary artery disease. Current Cardiology Reports 2:1, 61-68
CrossRef264
AGM van den Belt, MH Prins, AWA Lensing, AA Castro, OAC Clark, AN Atallah, E Burihan. 1999. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. .
CrossRef265
Muhammad M. Mamdani, Eric Racine, Scott McCreadie, Chris Zimmerman, Tami L. O’Sullivan, Gail Jensen, Paul Ragatzki, James G. Stevenson. (1999) Clinical and Economic Effectiveness of an Inpatient Anticoagulation Service. Pharmacotherapy 19:9, 1064-1074
CrossRef266
Ryan R. Davies, Michael A. Coady, Graeme L. Hammond, John A. Elefteriades, Richard J. Gusberg. (1999) Low molecular weight heparin: An evaluation of current and potential clinical utility in surgery. International Journal of Angiology 8:4, 203-215
CrossRef267
Christopher P. Cannon. (1999) Low molecular weight heparin in acute coronary syndromes. Current Cardiology Reports 1:3, 206-211
CrossRef268
Paolo Prandoni, Pier Mannuccio Mannucci. (1999) Deep-vein thrombosis of the lower limbs: diagnosis and management. Best Practice & Research Clinical Haematology 12:3, 533-554
CrossRef269
Jose A. Gonzalez-Fajardo, Emilio Arreba, Javier Castrodeza, Jose L. Perez, Leopold Fernandez, Ignacio Agundez, Antonio M. Mateo, Santiago Carrera, Vicente Gutiérrez, Carlos Vaquero. (1999) Venographic comparison of subcutaneous low–molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. Journal of Vascular Surgery 30:2, 283-292
CrossRef270
Alexander Mayer, Norbert Vogel, Pol Maria Rommens. (1999) Thromboembolische komplikationen bei patienten mit becken- und azetabulumfrakturen Diagnostik, therapie, prevention. Unfallchirurgie 25:3-4, 183-192
CrossRef271
Gary E. Raskob. (1999) Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Current Opinion in Pulmonary Medicine 5:4, 216
CrossRef272
David Bergqvist, Bengt Jönsson. (1999) Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement. Value in Health 2:4, 288-294
CrossRef273
Carsten Ranke, Hans-Joachim Trappe. (1999) Update Angiologie. Medizinische Klinik 94:5, 251-263
CrossRef274
J HOUDE, G STEINBERG. (1999) Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. The Journal of Arthroplasty 14:3, 372-374
CrossRef275
Hazzaa Al-Zahrani, Shannon M. Bates, Jeffrey I. Weitz. (1999) Deep vein thrombosis. Current Treatment Options in Cardiovascular Medicine 1:1, 43-53
CrossRef276
M. J. Kovacs, M. Keeney, K. Mackinnon, E. Boyle. (1999) Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clinical and Laboratory Haematology 21:1, 55-60
CrossRef277
Edward C. Grendys, James V. Fiorica. (1999) Advances in the prevention and treatment of deep vein thrombosis and pulmonary embolism. Current Opinion in Obstetrics and Gynaecology 11:1, 71-79
CrossRef278
James N. Huang, Akiko Shimamura. (1998) LOW-MOLECULAR-WEIGHT HEPARINS. Hematology/Oncology Clinics of North America 12:6, 1251-1281
CrossRef279
Mohammed A Quader, Lisa S Stump, Bauer E Sumpio. (1998) Low molecular weight heparins: current use and indications. Journal of the American College of Surgeons 187:6, 641-658
CrossRef280
D STRANDNESSJR. (1998) Presidential address to the 1998 American Venous Forum: Where are we now? Where are we going? Inching forward. Journal of Vascular Surgery 28:5, 761-766
CrossRef281
Joaquim S. Couto MD. (1998) Evidence-based medicine: a Kuhnian perspective of a transvestite non-theory. Journal of Evaluation in Clinical Practice 4:4, 267-275
CrossRef282
HAYWOOD L. BROWN, RENEE A. BOBROWSKI. (1998) Anticoagulation. Clinical Obstetrics and Gynecology 41:3, 545-554
CrossRef283
Evelyn R Hermes De Santis, Betsy S Laumeister, Vidhu Bansal, Vandana Kataria, Preeti Loomba, Elizabeth Sparkman. (1998) Low-molecular-weight heparin in the prevention and treatment of thromboembolic disorders. Disease Management and Clinical Outcomes 1:5, 166-174
CrossRef284
Philip MW Bath. (1998) Low molecular weight heparin in acute stroke. Expert Opinion on Investigational Drugs 7:8, 1323-1330
CrossRef285
David Bergqvist. (1998) MODERN ASPECTS OF PROPHYLAXIS AND THERAPY FOR VENOUS THROMBO-EMBOLIC DISEASE. ANZ Journal of Surgery 68:7, 463-468
CrossRef286
P.E. Rose, D. Fitzmaurice. (1998) New approaches to the delivery of anticoagulant services. Blood Reviews 12:2, 84-90
CrossRef287
S C Litin, J A Heit, K A Mees. (1998) Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. The Thrombophilia Center Investigators.. Mayo Clinic Proceedings 73:6, 545-550
CrossRef288
Graham F. Pineo, Russell D. Hull. (1998) UNFRACTIONATED AND LOW-MOLECULAR-WEIGHT HEPARIN. Medical Clinics of North America 82:3, 587-599
CrossRef289
Sylvia K. Haas. (1998) TREATMENT OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM. Medical Clinics of North America 82:3, 495-510
CrossRef290
Rodger L. Bick, Sylvia K. Haas. (1998) INTERNATIONAL CONSENSUS RECOMMENDATIONS. Medical Clinics of North America 82:3, 613-633
CrossRef291
Beatrice K. Launius, B Diane Graham. (1998) Understanding and Preventing Deep Vein Thrombosis and Pulmonary Embolism. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9:1, 91-99
CrossRef292
Jules A Shafer. (1998) Cardiovascular chemotherapy: anticoagulants. Current Opinion in Chemical Biology 2:4, 458-465
CrossRef293
Liguo Chi, Karen L Rogers, Andrew CG Uprichard, Kim P. Gallagher. (1997) The therapeutic potential of novel anticoagulants. Expert Opinion on Investigational Drugs 6:11, 1591-1605
CrossRef294
James S.T. Yao. (1997) Presidential address: Venous disorders—Reflections of the past three decades. Journal of Vascular Surgery 26:5, 727-735
CrossRef295
Wood, Alastair J.J., , Weitz, Jeffrey I., . (1997) Low-Molecular-Weight Heparins. New England Journal of Medicine 337:10, 688-699
Full Text296
Simonneau, Gérald, Sors, Hervé, Charbonnier, Bernard, Page, Yves, Laaban, Jean-Pierre, Azarian, Réza, Laurent, Marcel, Hirsch, Jean-Lou, Ferrari, Emile, Bosson, Jean-Luc, Mottier, Dominique, Beau, Bertrand, . (1997) A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism. New England Journal of Medicine 337:10, 663-669
Full Text297
The Columbus Investigators. (1997) Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. New England Journal of Medicine 337:10, 657-662
Full Text298
Denise Walsh-McMonagle, David Green. (1997) Low-molecular-weight heparin in the management of Tyrousseau's syndrome. Cancer 80:4, 649-655
CrossRef299
Armstrong, Paul W., . (1997) Heparin in Acute Coronary Disease — Requiem for a Heavyweight?. New England Journal of Medicine 337:7, 492-494
Full Text300
Cohen, Marc, Demers, Christine, Gurfinkel, Enrique P., Turpie, Alexander G.G., Fromell, Gregg J., Goodman, Shaun, Langer, Anatoly, Califf, Robert M., Fox, Keith A.A., Premmereur, Jerome, Bigonzi, Frederique, Stephens, Jim, Weatherley, Beth. (1997) A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. New England Journal of Medicine 337:7, 447-452
Full Text301
Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Rana Clarizio, Jeanine M Walenga. (1997) Low molecular weight heparins: a developmental perspective. Expert Opinion on Investigational Drugs 6:6, 705-733
CrossRef302
Alan B Grosset, Theodore E Spiro, Julia Beynon, George M Rodgers. (1997) ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN SUPPRESSES PROTHROMBIN ACTIVATION MORE EFFECTIVELY THAN UNFRACTIONATED HEPARIN IN PATIENTS TREATED FOR VENOUS THROMBOEMBOLISM. Thrombosis Research 86:5, 349-354
CrossRef303
William D. McMillan, Walter J. McCarthy, Samuel J. Lin, Jon S. Matsumura, William H. Pearce, James S.T. Yao. (1997) Perioperative low molecular weight heparin for infrageniculate bypass. Journal of Vascular Surgery 25:5, 796-802
CrossRef304
G Grateau, L Chauvenet, S Oudard, C Bachmeyer, L Capron, MH Horellou, MM Samama. (1997) Accidents hémorragiques graves lors d'un traitement par héparine de bas poids moléculaire. À propos de deux observations. La Revue de Médecine Interne 18:5, 411-415
CrossRef305
Graham F. Pineo, MD, Russell D. Hull, MD. (1997) LOW-MOLECULAR-WEIGHT HEPARIN: Prophylaxis and Treatment of Venous Thromboembolism. Annual Review of Medicine 48:1, 79-91
CrossRef306
Wood, Alastair J.J., , Ginsberg, Jeffrey Stephen, . (1996) Management of Venous Thromboembolism. New England Journal of Medicine 335:24, 1816-1829
Full Text307
HGM Shetty, PA Routledge. (1996) Prevention and treatment of venous thromboembolism in the elderly. Reviews in Clinical Gerontology 6:04, 325
CrossRef308
John V. L. Sheffield, Eric B. Larson. (1996) General internal medicine update. Journal of General Internal Medicine 11:10, 613-621
CrossRef309
(1996) Unfractionated versus Low-Molecular-Weight Heparin for Deep Venous Thrombosis. New England Journal of Medicine 335:9, 670-672
Full Text310
Schafer, Andrew I., . (1996) Low-Molecular-Weight Heparin — An Opportunity for Home Treatment of Venous Thrombosis. New England Journal of Medicine 334:11, 724-726
Full Text311
Hugo Cate, Michael T. Nurmohamed, Jan W. Cate. (1996) Developments in antithrombotic therapy: state of the art anno 1996. Pharmacy World and Science 18:6, 195-203
CrossRef
- Letters
